Genetic Clues for Skin Cancer Therapies Washington DC

Scientists have isolated a group of genetic mutations involved in the growth of melanoma, the deadliest form of skin cancer. Their work may lead to therapies with existing drugs that target the same mutations. Led by Yardena Samuels of the National Human Genome Research Institute, the research team from the U.S. National Institutes of Health (NIH) sequenced the protein tyrosine kinase (PTK) gene family in tumor and blood samples from people with metastatic melanoma.

David A Spott, MD
(301) 868-7077
9131 Piscataway Rd
Clinton, MD
Business
David A Spott MD
Specialties
Dermatology

Data Provided by:
Giannelli Vincenzo MD
(202) 775-1792
2440 M St Nw
Washington, DC
 
Zenona W Mally, MD
1634 I St NW
Washington, DC
Specialties
Dermatology
Gender
Female
Education
Medical School: Univ Of Toronto, Fac Of Med, Toronto, Ont, Canada
Graduation Year: 1958

Data Provided by:
Edward Harvey Stolar, MD
(202) 659-2223
1712 I St NW Ste 712
Washington, DC
Specialties
Dermatology
Gender
Male
Education
Medical School: George Washington Univ Sch Of Med & Hlth Sci, Washington Dc 20037
Graduation Year: 1981
Hospital
Hospital: George Washington Univ Hosp, Washington, Dc

Data Provided by:
Dr.David Cowan
(877) 661-3376
1120 19th Street Northwest #200
Washington, DC
Gender
M
Speciality
Dermatologist
General Information
Accepting New Patients: Yes
RateMD Rating
2.8, out of 5 based on 3, reviews.

Data Provided by:
Signature Certified Laser Hair Removal Center DC
(888) 517-4187
Washington, DC
 
Sarah G Williams, MD
(202) 782-1774
631 D St NW Apt 1129
Washington, DC
Specialties
Dermatology, Dermatopathology
Gender
Female
Education
Medical School: Univ Of Sc Sch Of Med, Columbia Sc 29208
Graduation Year: 1996

Data Provided by:
Suneeta Singh Walia, MD
(202) 338-1814
Washington, DC
Specialties
Dermatology
Gender
Female
Education
Medical School: La State Univ Sch Of Med In New Orleans, New Orleans La 70112
Graduation Year: 2001

Data Provided by:
Carmen Myrie Williams, MD
(202) 955-6995
1120 19th St NW Ste 250
Washington, DC
Specialties
Dermatology
Gender
Female
Education
Medical School: New York Univ Sch Of Med, New York Ny 10016
Graduation Year: 1974

Data Provided by:
Thomas M Williams, MD
(202) 865-3290
2041 Georgia Ave NW
Washington, DC
Specialties
Dermatology
Gender
Male
Education
Medical School: Meharry Med Coll Sch Of Med, Nashville Tn 37208
Graduation Year: 1953

Data Provided by:
Data Provided by:

Genetic Clues for Skin Cancer Therapies

Provided By:

MONDAY, Aug. 31 (HealthDay News) -- Scientists have isolated a group of genetic mutations involved in the growth of melanoma, the deadliest form of skin cancer. Their work may lead to therapies with existing drugs that target the same mutations.

Led by Yardena Samuels of the National Human Genome Research Institute, the research team from the U.S. National Institutes of Health (NIH) sequenced the protein tyrosine kinase (PTK) gene family in tumor and blood samples from people with metastatic melanoma. Their study is published in the September issue of the journal Nature Genetics.

"We have found what appears to be an Achilles' heel of a sizable share of melanomas," Samuels, an investigator in the cancer genetics branch of the institute's Division of Intramural Research, said in a NIH news release.

The PTK family includes many genes that, when mutated, promote many types of cancer, including brain, gastric and lung malignancies, according to background information provided in the news release. In the new NIH study, one PTK gene that appeared particularly suspicious was the ERBB4 gene. Scientists found ERBB4 mutations in 19 percent of patients' tumors, making it the most frequently mutated PTK gene in melanoma. Additional lab studies found that melanoma cells with the ERBB4 defect were dependent on the mutant gene for their growth.

The researchers also found that two additional PTK genes -- FLT1 and PTK2B -- were mutated in about 10 percent of the tumor samples.

The discoveries could open up new avenues for therapies. For example, the researchers discovered that melanoma cells grew much more slowly when exposed to lapatinib (Tykerb), a chemotherapy drug that inhibits ERBB4. Lapatinib is already in use by some breast cancer patients. The NIH team is planning a clinical trial using lapatinib in patients with metastatic melanoma harboring ERBB4 mutations.

"Though additional work is needed to gain a more complete understanding of these genetic mutations and their roles in cancer biology, our findings open the door to pursuing specific therapies that may prove useful for the treatment of melanoma with ERBB4 mutations," Samuels stated.

More information

The American Cancer Society has more on melanoma.

SOURCE: U.S. National Institutes of Health, news release, Aug. 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com